Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Research & Development (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Research & Development data on record, last reported at $20.4 million in Q3 2025.

  • For Q3 2025, Research & Development rose 72.48% year-over-year to $20.4 million; the TTM value through Sep 2025 reached $75.9 million, up 67.35%, while the annual FY2024 figure was $50.0 million, 37.18% up from the prior year.
  • Research & Development reached $20.4 million in Q3 2025 per CAPR's latest filing, down from $22.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.0 million in Q2 2025 and bottomed at $2.5 million in Q3 2021.
  • Average Research & Development over 5 years is $9.6 million, with a median of $8.8 million recorded in 2023.
  • The widest YoY moves for Research & Development: up 185.68% in 2021, down 4.39% in 2021.
  • A 5-year view of Research & Development shows it stood at $4.3 million in 2021, then surged by 45.29% to $6.2 million in 2022, then skyrocketed by 59.23% to $9.9 million in 2023, then skyrocketed by 46.76% to $14.6 million in 2024, then skyrocketed by 39.4% to $20.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $20.4 million in Q3 2025, $22.0 million in Q2 2025, and $18.9 million in Q1 2025.